Trial Profile
Personalization of Long-Term Antiplatelet Therapy Using a Novel Combined Demographic/Pharmacogenomic Strategy - The RAPID EXTEND Randomized Study
Status:
Suspended
Phase of Trial:
Phase IV
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Aspirin (Primary) ; Clopidogrel (Primary) ; Ticagrelor (Primary)
- Indications Acute coronary syndromes; Arterial occlusive disorders; Thrombosis
- Focus Therapeutic Use
- Acronyms RAPID EXTEND
- 12 Jan 2024 Planned End Date changed from 1 Oct 2023 to 1 Sep 2024.
- 12 Jan 2024 Planned primary completion date changed from 1 Oct 2023 to 1 Mar 2024.
- 17 Feb 2022 Planned End Date changed from 1 Oct 2022 to 1 Oct 2023.